<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24098578</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>10</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapy.</ArticleTitle><Pagination><StartPage>e77133</StartPage><MedlinePgn>e77133</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e77133</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0077133</ELocationID><Abstract><AbstractText>Although several factors participating in enterovirus 71 (EV71) entry and replication had been reported, the precise mechanisms associated with these events are far from clear. In the present study, we showed that heat shock protein 90 (HSP90) is a key element associated with EV71 entry and replication in a human rhabdomyosarcoma of RD cells. Inhibition of HSP90 by pretreating host cells with HSP90&#x3b2; siRNA or blocking HSP90 with a HSP90-specific antibody or geldanamycin (GA), a specific inhibitor of HSP90, as well as recombinant HSP90&#x3b2; resulted in inhibiting viral entry and subsequent viral replication. Co-immunprecipitation of EV71 with recombinant HSP90&#x3b2; and colocalization of EV71-HSP90 in the cells demonstrated that HSP90 was physically associated with EV71 particles. HSP90 seems to mediate EV71 replication by preventing proteosomal degradation of the newly synthesized capsid proteins, but does not facilitate viral gene expression at transcriptional level. This was evident by post-treatment of host cells with GA, which did not affect the expression of viral transcripts but accelerated the degradation of viral capsid proteins and interfered with the formation of assembled virions. In vivo studies were carried out using human SCARB2-transgenic mice to evaluate the protection conferred by HSP90 inhibitor, 17-allyamino-17-demethoxygeldanamycin (17-AAG), an analog of geldanamycin, that elicited similar activity but with less toxicity. The results showed that the administration of 17-AAG twice conferred the resistance to hSCARB2 mice challenged with C2, C4, and B4 genotypes of EV71. Our data supports HSP90 plays an important role in EV71 infection. Targeting of HSP90 with clinically available drugs might provide a feasible therapeutic approach to treat EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsou</LastName><ForeName>Yueh-Liang</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli, County, Taiwan ; Graduate Program of Biotechnology in Medicine, Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yi-Wen</ForeName><Initials>YW</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Hsuen-Wen</ForeName><Initials>HW</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hsiang-Yin</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Hsiao-Yun</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shu-Ling</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chyi</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Chitra</LastName><ForeName>Ebenezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sia</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Yen-Hung</ForeName><Initials>YH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016227">Benzoquinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047029">Lactams, Macrocyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>4GY0AVT3L4</RegistryNumber><NameOfSubstance UI="C112765">tanespimycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016227" MajorTopicYN="N">Benzoquinones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018841" MajorTopicYN="N">HSP90 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047029" MajorTopicYN="N">Lactams, Macrocyclic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24098578</ArticleId><ArticleId IdType="pmc">PMC3788750</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0077133</ArticleId><ArticleId IdType="pii">PONE-D-12-36459</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT
et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med
341: 929-935. doi:10.1056/NEJM199909233411301. PubMed: 10498487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC
et al. (1999) Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis
29: 184-190. doi:10.1086/520149. PubMed: 10433583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/520149</ArticleId><ArticleId IdType="pubmed">10433583</ArticleId></ArticleIdList></Reference><Reference><Citation>
Liu CC, Tseng HW, Wang SM, Wang JR, Su IJ (2000) An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol
17: 23-30. doi:10.1016/S1386-6532(00)00068-8. PubMed: 10814935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6532(00)00068-8</ArticleId><ArticleId IdType="pubmed">10814935</ArticleId></ArticleIdList></Reference><Reference><Citation>
P&#xe9;rez-V&#xe9;lez CM, Anderson MS, Robinson CC, McFarland EJ, Nix WA
et al. (2007) Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis
45: 950-957. doi:10.1086/521895. PubMed: 17879907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/521895</ArticleId><ArticleId IdType="pubmed">17879907</ArticleId></ArticleIdList></Reference><Reference><Citation>
Huang CC, Liu CC, Chang YC, Chen CY, Wang ST
et al. (1999) Neurologic complications in children with enterovirus 71 infection. N Engl J Med
341: 936-942. doi:10.1056/NEJM199909233411302. PubMed: 10498488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411302</ArticleId><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>
AbuBakar S, Chee HY, Al-Kobaisi MF, Xiaoshan J, Chua KB
et al. (1999) Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res
61: 1-9. doi:10.1016/S0168-1702(99)00019-2. PubMed: 10426204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-1702(99)00019-2</ArticleId><ArticleId IdType="pubmed">10426204</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lin KH, Hwang KP, Ke GM, Wang CF, Ke LY
et al. (2006) Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J Med Virol
78: 254-262. doi:10.1002/jmv.20534. PubMed: 16372302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20534</ArticleId><ArticleId IdType="pubmed">16372302</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lu CH, Huang SW, Lai YL, Lin CP, Shih CH
et al. (2008) On the relationship between the protein structure and protein dynamics. Proteins
72: 625-634. doi:10.1002/prot.21954. PubMed: 18247347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.21954</ArticleId><ArticleId IdType="pubmed">18247347</ArticleId></ArticleIdList></Reference><Reference><Citation>
Melnick JL, Schmidt NJ, Mirkovic RR, Chumakov MP, Lavrova IK
et al. (1980) Identification of Bulgarian strain 258 of enterovirus 71. Intervirology
12: 297-302. PubMed: 6244233.</Citation><ArticleIdList><ArticleId IdType="pubmed">6244233</ArticleId></ArticleIdList></Reference><Reference><Citation>
Nagy G, Tak&#xe1;tsy S, Kuk&#xe1;n E, Mih&#xe1;ly I, D&#xf6;m&#xf6;k I (1982) Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol
71: 217-227. doi:10.1007/BF01314873. PubMed: 6285858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01314873</ArticleId><ArticleId IdType="pubmed">6285858</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wu TN, Tsai SF, Li SF, Lee TF, Huang TM
et al. (1999) Sentinel surveillance for enterovirus 71, Taiwan, 1998. Emerg Infect Dis
5: 458-460. doi:10.3201/eid0503.990321. PubMed: 10341187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0503.990321</ArticleId><ArticleId IdType="pmc">PMC2640775</ArticleId><ArticleId IdType="pubmed">10341187</ArticleId></ArticleIdList></Reference><Reference><Citation>
Chen YC, Yu CK, Wang YF, Liu CC, Su IJ
et al. (2004) A murine oral enterovirus 71 infection model with central nervous system involvement. J Gen Virol
85: 69-77. doi:10.1099/vir.0.19423-0. PubMed: 14718621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.19423-0</ArticleId><ArticleId IdType="pubmed">14718621</ArticleId></ArticleIdList></Reference><Reference><Citation>
Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A
et al. (2004) Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol
85: 2981-2989. doi:10.1099/vir.0.79883-0. PubMed: 15448361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79883-0</ArticleId><ArticleId IdType="pubmed">15448361</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ong KC, Badmanathan M, Devi S, Leong KL, Cardosa MJ
et al. (2008) Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J Neuropathol Exp Neurol
67: 532-542. doi:10.1097/NEN.0b013e31817713e7. PubMed: 18520772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713e7</ArticleId><ArticleId IdType="pubmed">18520772</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wang YF, Chou CT, Lei HY, Liu CC, Wang SM
et al. (2004) A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol
78: 7916-7924. doi:10.1128/JVI.78.15.7916-7924.2004. PubMed: 15254164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.7916-7924.2004</ArticleId><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>
Weng KF, Chen LL, Huang PN, Shih SR (2010) Neural pathogenesis of enterovirus 71 infection. Microbes Infect
12: 505-510. doi:10.1016/j.micinf.2010.03.006. PubMed: 20348010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.03.006</ArticleId><ArticleId IdType="pubmed">20348010</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wu CN, Lin YC, Fann C, Liao NS, Shih SR
et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine
20: 895-904. doi:10.1016/S0264-410X(01)00385-1. PubMed: 11738755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ et al. (2012) A non mouse-adapted Enterovirus 71 (EV71) strain exhibits neurotropism causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86(4):2131-31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hashimoto I, Hagiwara A, Kodama H (1978) Neurovirulence in cynomolgus monkeys of enterovirus 71 isolated from a patient with hand, foot and mouth disease. Arch Virol
56: 257-261. doi:10.1007/BF01317855. PubMed: 205198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01317855</ArticleId><ArticleId IdType="pubmed">205198</ArticleId></ArticleIdList></Reference><Reference><Citation>
Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T
et al. (2009) Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med
15: 794-797. doi:10.1038/nm.1961. PubMed: 19543284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>
Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T
et al. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med
15: 798-801. doi:10.1038/nm.1992. PubMed: 19543282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lin YW, Yu SL, Shao HY, Lin HY, Liu CC
et al. (2013) Human SCARB2 Transgenic Mice as an Infectious Animal Model for Enterovirus 71. PLOS ONE
8: e57591. doi:10.1371/journal.pone.0057591. PubMed: 23451246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057591</ArticleId><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Dong W, Quan X, Ma C, Qin C et al. (2012) Transgenic expression of human P-selectin glycoprotein ligand-1 is not sufficient for enterovirus 71 infection in mice. Arch Virol 157(3):539-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">22187102</ArticleId></ArticleIdList></Reference><Reference><Citation>
Yang SL, Chou YT, Wu CN, Ho MS (2011) Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol
85: 11809-11820. doi:10.1128/JVI.00297-11. PubMed: 21900167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00297-11</ArticleId><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tan CW, Poh CL, Sam IC, Chan YF (2013) Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol
87: 611-620. doi:10.1128/JVI.02226-12. PubMed: 23097443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>
Yang B, Chuang H, Yang KD (2009) Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J
6: 141. doi:10.1186/1743-422X-6-141. PubMed: 19751532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-6-141</ArticleId><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lin JY, Li ML, Huang PN, Chien KY, Horng JT
et al. (2008) Heterogeneous nuclear ribonuclear protein K interacts with the enterovirus 71 5' untranslated region and participates in virus replication. J Gen Virol
89: 2540-2549. doi:10.1099/vir.0.2008/003673-0. PubMed: 18796723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/003673-0</ArticleId><ArticleId IdType="pubmed">18796723</ArticleId></ArticleIdList></Reference><Reference><Citation>
Huang PN, Lin JY, Locker N, Kung YA, Hung CT
et al. (2011) Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids Res
39: 9633-9648. doi:10.1093/nar/gkr682. PubMed: 21880596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr682</ArticleId><ArticleId IdType="pmc">PMC3239202</ArticleId><ArticleId IdType="pubmed">21880596</ArticleId></ArticleIdList></Reference><Reference><Citation>
Stuart K, Brennan M, French J, Houssami N, Boyages J (2006) Life after breast cancer. Aust Fam Physician
35: 219-224. PubMed: 16642238.</Citation><ArticleIdList><ArticleId IdType="pubmed">16642238</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ochel HJ, Eichhorn K, Gademann G (2001) Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones
6: 105-112. doi:10.1379/1466-1268(2001)006. PubMed: 11599571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1379/1466-1268(2001)006</ArticleId><ArticleId IdType="pmc">PMC434387</ArticleId><ArticleId IdType="pubmed">11599571</ArticleId></ArticleIdList></Reference><Reference><Citation>
Sharp S, Workman P (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res
95: 323-348. doi:10.1016/S0065-230X(06)95009-X. PubMed: 16860662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-230X(06)95009-X</ArticleId><ArticleId IdType="pubmed">16860662</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wegele H, M&#xfc;ller L, Buchner J (2004) Hsp70 and Hsp90--a relay team for protein folding. Rev Physiol Biochem Pharmacol
151: 1-44. doi:10.1007/s10254-003-0021-1. PubMed: 14740253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10254-003-0021-1</ArticleId><ArticleId IdType="pubmed">14740253</ArticleId></ArticleIdList></Reference><Reference><Citation>
Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci
31: 164-172. doi:10.1016/j.tibs.2006.01.006. PubMed: 16483782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2006.01.006</ArticleId><ArticleId IdType="pubmed">16483782</ArticleId></ArticleIdList></Reference><Reference><Citation>
Bukau B, Horwich AL (1998) The Hsp70 and Hsp60 chaperone machines. Cell
92: 351-366. doi:10.1016/S0092-8674(00)80928-9. PubMed: 9476895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80928-9</ArticleId><ArticleId IdType="pubmed">9476895</ArticleId></ArticleIdList></Reference><Reference><Citation>
Geller R, Vignuzzi M, Andino R, Frydman J (2007) Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev
21: 195-205. doi:10.1101/gad.1505307. PubMed: 17234885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1505307</ArticleId><ArticleId IdType="pmc">PMC1770902</ArticleId><ArticleId IdType="pubmed">17234885</ArticleId></ArticleIdList></Reference><Reference><Citation>
Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH
et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine
26: 1855-1862. doi:10.1016/j.vaccine.2008.01.058. PubMed: 18329759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>
Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT
et al. (2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res
125: 61-68. doi:10.1016/j.virusres.2006.12.005. PubMed: 17222936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tung WS, Bakar SA, Sekawi Z, Rosli R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther
5: 6. doi:10.1186/1479-0556-5-6. PubMed: 17445254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF
et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature
425: 407-410. doi:10.1038/nature01913. PubMed: 14508491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01913</ArticleId><ArticleId IdType="pubmed">14508491</ArticleId></ArticleIdList></Reference><Reference><Citation>
Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C
et al. (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol
6: 507-514. doi:10.1038/ncb1131. PubMed: 15146192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1131</ArticleId><ArticleId IdType="pubmed">15146192</ArticleId></ArticleIdList></Reference><Reference><Citation>
Sidera K, Samiotaki M, Yfanti E, Panayotou G, Patsavoudi E (2004) Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J Biol Chem
279: 45379-45388. doi:10.1074/jbc.M405486200. PubMed: 15302889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M405486200</ArticleId><ArticleId IdType="pubmed">15302889</ArticleId></ArticleIdList></Reference><Reference><Citation>
Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M
et al. (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem
276: 3702-3708. doi:10.1074/jbc.M006864200. PubMed: 11071886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M006864200</ArticleId><ArticleId IdType="pubmed">11071886</ArticleId></ArticleIdList></Reference><Reference><Citation>
Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol
15: 419-424. doi:10.1097/00001622-200311000-00003. PubMed: 14624223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001622-200311000-00003</ArticleId><ArticleId IdType="pubmed">14624223</ArticleId></ArticleIdList></Reference><Reference><Citation>
Isaacs JS, Xu W, Neckers L (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell
3: 213-217. doi:10.1016/S1535-6108(03)00029-1. PubMed: 12676580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1535-6108(03)00029-1</ArticleId><ArticleId IdType="pubmed">12676580</ArticleId></ArticleIdList></Reference><Reference><Citation>
Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ
et al. (2011) Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine
29: 4362-4372. doi:10.1016/j.vaccine.2011.04.010. PubMed: 21501643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>
Pratt WB, Toft DO (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood)
228: 111-133. PubMed: 12563018.</Citation><ArticleIdList><ArticleId IdType="pubmed">12563018</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lee DH, Goldberg AL (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol
8: 397-403. doi:10.1016/S0962-8924(98)01346-4. PubMed: 9789328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0962-8924(98)01346-4</ArticleId><ArticleId IdType="pubmed">9789328</ArticleId></ArticleIdList></Reference><Reference><Citation>
Neckers L, Schulte TW, Mimnaugh E (1999) Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs
17: 361-373. doi:10.1023/A:1006382320697. PubMed: 10759403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1006382320697</ArticleId><ArticleId IdType="pubmed">10759403</ArticleId></ArticleIdList></Reference><Reference><Citation>
Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol
36: 305-315. doi:10.1007/BF00689048. PubMed: 7628050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00689048</ArticleId><ArticleId IdType="pubmed">7628050</ArticleId></ArticleIdList></Reference><Reference><Citation>
Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol
42: 273-279. doi:10.1007/s002800050817. PubMed: 9744771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002800050817</ArticleId><ArticleId IdType="pubmed">9744771</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaze ER, Lambert AL, Smith AC, Page JG, Johnson WD et al. (2005) Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer chemotherapy and pharmacology 56: 637-647.</Citation><ArticleIdList><ArticleId IdType="pubmed">15986212</ArticleId></ArticleIdList></Reference><Reference><Citation>
Schneider-Schaulies J (2000) Cellular receptors for viruses: links to tropism and pathogenesis. J Gen Virol
81: 1413-1429. PubMed: 10811925.</Citation><ArticleIdList><ArticleId IdType="pubmed">10811925</ArticleId></ArticleIdList></Reference><Reference><Citation>
Smith AE, Helenius A (2004) How viruses enter animal cells. Science
304: 237-242. doi:10.1126/science.1094823. PubMed: 15073366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1094823</ArticleId><ArticleId IdType="pubmed">15073366</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lin YW, Lin HY, Tsou YL, Chitra E, Hsiao KN
et al. (2012) Human SCARB2-mediated entry and endocytosis of EV71. PLOS ONE
7: e30507. doi:10.1371/journal.pone.0030507. PubMed: 22272359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030507</ArticleId><ArticleId IdType="pmc">PMC3260287</ArticleId><ArticleId IdType="pubmed">22272359</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hung CY, Tsai MC, Wu YP, Wang RY (2011) Identification of heat-shock protein 90 beta in Japanese encephalitis virus-induced secretion proteins. J Gen Virol
92: 2803-2809. doi:10.1099/vir.0.033993-0. PubMed: 21813703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.033993-0</ArticleId><ArticleId IdType="pubmed">21813703</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kawashima D, Kanda T, Murata T, Saito S, Sugimoto A
et al. (2013) Nuclear Transport of Epstein-Barr Virus DNA Polymerase is dependent on the BMRF1 Polymerase Processivity Factor and Molecular Chaperone Hsp90. J Virol, 87: 6482&#x2013;91. PubMed: 23552409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648106</ArticleId><ArticleId IdType="pubmed">23552409</ArticleId></ArticleIdList></Reference><Reference><Citation>
Reyes-Del Valle J, Ch&#xe1;vez-Salinas S, Medina F, Del Angel RM (2005) Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J Virol
79: 4557-4567. doi:10.1128/JVI.79.8.4557-4567.2005. PubMed: 15795242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.8.4557-4567.2005</ArticleId><ArticleId IdType="pmc">PMC1069525</ArticleId><ArticleId IdType="pubmed">15795242</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lin TW, Lo CW, Lai SY, Fan RJ, Lo CJ
et al. (2007) Chicken heat shock protein 90 is a component of the putative cellular receptor complex of infectious bursal disease virus. J Virol
81: 8730-8741. doi:10.1128/JVI.00332-07. PubMed: 17522206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00332-07</ArticleId><ArticleId IdType="pmc">PMC1951386</ArticleId><ArticleId IdType="pubmed">17522206</ArticleId></ArticleIdList></Reference><Reference><Citation>
Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C
et al. (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med
11: 1088-1095. doi:10.1038/nm1298. PubMed: 16155577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1298</ArticleId><ArticleId IdType="pubmed">16155577</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wang RY, Kuo RL, Ma WC, Huang HI, Yu JS
et al. (2013) Heat shock protein-90-beta facilitates enterovirus 71 viral particles assembly. Virology, 443: 236&#x2013;47. PubMed: 23711381.</Citation><ArticleIdList><ArticleId IdType="pubmed">23711381</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wu SC, Liu CC, Lian WC (2004) Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine
22: 3858-3864. doi:10.1016/j.vaccine.2004.05.037. PubMed: 15364432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.05.037</ArticleId><ArticleId IdType="pubmed">15364432</ArticleId></ArticleIdList></Reference><Reference><Citation>
Liu CC, Lian WC, Butler M, Wu SC (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine
25: 19-24. doi:10.1016/j.vaccine.2006.06.083. PubMed: 16919374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.06.083</ArticleId><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference><Reference><Citation>
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem
72: 248-254. doi:10.1016/0003-2697(76)90527-3. PubMed: 942051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-2697(76)90527-3</ArticleId><ArticleId IdType="pubmed">942051</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H (1938) A simple method of estimating 50 percent end-points. Am J Hyg 27: 493-497.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>